Erectile dysfunction among hypertensive men in a rapidly developing country.
BACKGROUND
Previous studies have supported the association between hypertension and erectile dysfunction (ED). In addition, a significant correlation between hypertension in men and ED has been well established.


OBJECTIVE
The aim of this study was to investigate the prevalence of ED, its severity and other sexual function domains in hypertensive patients in Qatar.


METHODS
Cross-sectional study conducted between January and December 2006 at the Hamad General Hospital.


METHODS
Qatari and nonQatari nationals 25 to 75 years of age were approached to participate in this study, 642 (75.5%) gave their consent.


METHODS
Qatari and nonQatari men aged 25 to 75 years who gave consent were interviewed face-to-face. Sexual function was evaluated with the International index of erectile function.


RESULTS
A total of 642 (75.5%) men responded, mean age of subjects was 57.1 +/- 11.9 years. The prevalence of ED in hypertensive patients was 58.3%. 21.2% of hypertensive men reported severe ED, 20.7% moderate ED and 16.4% mild ED. The comorbidities and risk factors were significantly more prominent in ED patients than in those with normal ED for hypercholesterolemia (P=0.009), diabetes (P=0.022) for hypertriglyceridemia (P=0.033) and myocardial ischemia (P=0.042).


CONCLUSIONS
Our results have shown a greater prevalence of ED in the hypertensive men in the population of Qatar. The presence of another risk factor in addition to elevated blood pressure can increase the likelihood of ED.
Bener
Abdulbari
A
Department of Medical Statistics and Epidemiology, Hamad Medical Corporation and Department Evidence for Population Health Unit, School of Epidemiology and Health Sciences, The University of Manchester, Manchester, UK.
Al-Ansari
Abdullah
A
Afifi
Mustafa
M
Krishna
Prasad V
PV
Asian J Androl. 2006 Mar;8(2):177-82
16491268
Am J Hypertens. 2004 Feb;17(2):139-45
14751656
Urology. 2004 Dec;64(6):1196-201
15596196
J Androl. 2006 May-Jun;27(3):469-77
16339456
Int J Impot Res. 1999 Dec;11(6):319-26
10637462
BJU Int. 1999 Jul;84(1):50-6
10444124
Med Clin (Barc). 2002 Oct 26;119(14):521-6
12421518
Clin Cardiol. 2003 Jan;26(1):25-30
12539809
J Hypertens. 2003 Nov;21(11):1983-92
14597836
Urology. 2006 Mar;67(3):575-8
16527582
J Urol. 1994 Jan;151(1):54-61
8254833
Int J Impot Res. 2003 Apr;15 Suppl 1:S8-14
12825103
Eur J Clin Pharmacol. 2002 Jun;58(3):177-80
12107602
Urology. 1999 Aug;54(2):346-51
10443736
Am J Hypertens. 1999 Mar;12(3):271-5
10192229
J Urol. 2000 Oct;164(4):1188-91
10992363
Am J Hypertens. 2005 Mar;18(3):427-30
15797665
Adverse Drug React Toxicol Rev. 1999 Mar;18(1):5-24
10401520
Urology. 1997 Jun;49(6):822-30
9187685
Curr Hypertens Rep. 2002 Jun;4(3):221-8
12003705
Eur Urol. 2005 Jan;47(1):80-5; discussion 85-6
15582253
Med Clin North Am. 1997 Nov;81(6):1305-17
9356600
Saudi Med J. 2004 Jul;25(7):918-22
15235700